Analysis of United States Drug Patent 9,499,545: Ocaliva (Obeticholic Acid)
United States Patent 9,499,545, issued on November 22, 2016, to Intercept Pharmaceuticals, Inc., covers obeticholic acid (OCA) and its use in treating primary biliary cholangitis (PBC). The patent's claims define the chemical structure of OCA and its therapeutic application. The patent landscape surrounding OCA is characterized by a series of granted patents covering composition of matter, formulation, and method of use, with strategic patent term extensions in place for Ocaliva, the branded drug product.
What is the Scope and What are the Key Claims of US Patent 9,499,545?
US Patent 9,499,545, titled "USE OF OBETICHOLIC ACID FOR TREATMENT OF PRIMARY BILIARY CHOLANGITIS," broadly claims the use of obeticholic acid for treating PBC. The patent defines obeticholic acid as a specific chemical entity.
The patent's primary claims focus on the therapeutic method.
- Claim 1: A method of treating primary biliary cholangitis in a subject, comprising administering to the subject an effective amount of obeticholic acid or a pharmaceutically acceptable salt thereof.
This foundational claim establishes the core therapeutic application of OCA for PBC. Subsequent claims within the patent refine aspects of the treatment, such as dosage and specific patient populations.
-
Claim 2: The method of claim 1, wherein the effective amount is from 5 mg to 50 mg of obeticholic acid per day.
-
Claim 3: The method of claim 1, wherein the effective amount is from 10 mg to 25 mg of obeticholic acid per day.
These claims specify dosage ranges, which are critical for defining the commercial viability and therapeutic efficacy of the drug.
- Claim 4: The method of claim 1, wherein the subject is a patient who has an inadequate therapeutic response to UDCA.
This claim targets a specific patient subset, addressing those who have not responded sufficiently to ursodeoxycholic acid (UDCA), a common first-line treatment for PBC. This segmentation is key for market differentiation and addressing unmet medical needs.
The patent also includes claims related to the formulation of OCA, although the primary focus of US Patent 9,499,545 is on the method of use. For instance, it implicitly covers formulations that can deliver the specified dosages.
What is the Patent Landscape for Obeticholic Acid and Related Compounds?
The patent landscape for obeticholic acid is characterized by a portfolio of intellectual property protecting various aspects of the drug, including its composition, manufacturing, formulation, and therapeutic uses. Intercept Pharmaceuticals has strategically built this portfolio to secure market exclusivity.
Key areas of patent protection include:
-
Composition of Matter Patents: These patents cover the obeticholic acid molecule itself. US Patent 6,353,045, issued in 2002 to Dartmouth College and later licensed to Intercept, is a foundational patent covering the chemical structure of OCA and related FXR agonists. This patent has long since expired.
-
Formulation Patents: Patents protecting specific pharmaceutical compositions of OCA designed for optimal delivery, stability, and patient compliance. These can include patents on specific salt forms, crystalline structures, or dosage forms (e.g., tablets).
-
Method of Use Patents: As exemplified by US Patent 9,499,545, these patents claim the use of OCA to treat specific diseases or conditions, such as PBC, nonalcoholic steatohepatitis (NASH), and potentially others. These patents are crucial for extending market exclusivity beyond the expiration of the original composition of matter patents.
-
Manufacturing Process Patents: Patents covering novel or efficient methods of synthesizing OCA.
-
Polymorph Patents: Patents that claim specific crystalline forms of OCA, which can have different physical properties (e.g., solubility, stability) and may be patentable as distinct entities.
Example of a related patent: US Patent 8,541,418, also assigned to Intercept Pharmaceuticals, Inc., titled "Obeticholic Acid Formulations and Methods of Use," claims specific solid dosage forms of obeticholic acid, including tablets, and their use in treating liver diseases. This patent complements US Patent 9,499,545 by protecting the physical form of the drug.
The expiration of early composition of matter patents opens the door for generic competition. However, the presence of later-expiring method of use and formulation patents, such as US Patent 9,499,545, provides a mechanism for extending market exclusivity.
What is the Patent Term and Exclusivity Status for Ocaliva (Obeticholic Acid)?
Ocaliva's market exclusivity is influenced by both the patent terms and regulatory exclusivities. United States Patent 9,499,545 has a statutory expiration date. However, due to the Hatch-Waxman Act, drug patents can be eligible for Patent Term Extension (PTE) to compensate for time lost during the FDA regulatory review process.
US Patent 9,499,545 was granted on November 22, 2016. Without PTE, its expiration would be November 22, 2033. Intercept Pharmaceuticals has likely sought and obtained PTE for this patent, which would extend its effective expiration date.
Patent Term Extension (PTE):
The PTE for US Patent 9,499,545, as indicated by the USPTO Orange Book (FDA's Approved Drug Products with Therapeutic Equivalence Evaluations), extends the patent term. The exact extension is calculated based on the patent term remaining after the drug's marketing approval. As of the latest available information, the PTE for US Patent 9,499,545 is active, significantly extending its protection beyond the original statutory expiration.
For Ocaliva, the primary indication for PBC, regulatory exclusivities also play a role:
- New Chemical Entity (NCE) Exclusivity: Typically 5 years from approval, though this applies to the initial approval of the drug product.
- Orphan Drug Exclusivity (ODE): For drugs approved to treat rare diseases, ODE provides 7 years of exclusivity from the date of approval. PBC is considered a rare disease, making Ocaliva eligible for ODE.
The interplay of PTE and ODE is crucial for understanding the full duration of market exclusivity for Ocaliva. The most effective strategies for market entry for biosimilar or generic competitors will depend on the precise expiration dates of all relevant patents and the exhaustion of regulatory exclusivities.
What are the Key Patent Challenges and Litigation Risks?
The patent landscape for a commercially successful drug like Ocaliva is often subject to legal challenges. Potential patent challenges and litigation risks associated with US Patent 9,499,545 and related patents include:
-
Invalidity Challenges: Generic drug manufacturers or other competitors may challenge the validity of the patent claims. Grounds for invalidity typically include:
- Anticipation (Lack of Novelty): Asserting that the claimed invention was already known or described in the prior art before the patent's filing date.
- Obviousness: Arguing that the claimed invention would have been obvious to a person skilled in the art at the time of filing, given the existing prior art.
- Indefiniteness: Claiming that the patent's claims are unclear or ambiguous, making it difficult to determine the scope of protection.
- Lack of Enablement or Written Description: Asserting that the patent does not adequately describe how to make and use the invention or does not clearly define what the inventor claims.
-
Non-Infringement Claims: Competitors may argue that their products or methods do not fall within the scope of the patent's claims, even if the patent is considered valid. This involves a detailed analysis of the patent's claim language and the accused product or method.
-
Post-Grant Review (PGR) and Inter Partes Review (IPR): These are administrative proceedings before the U.S. Patent and Trademark Office (USPTO) that allow third parties to challenge the validity of granted patent claims. These can be a more cost-effective and faster route to invalidate patents compared to district court litigation.
-
Antitrust and Competition Law Concerns: In some cases, the enforcement of patents, particularly through strategies like "evergreening" (obtaining patents on minor modifications to extend exclusivity), can lead to antitrust scrutiny.
Specific Litigation Landscape:
Intercept Pharmaceuticals has faced and is likely to continue to face patent litigation related to Ocaliva. Generic manufacturers often initiate Paragraph IV certifications under the Hatch-Waxman Act, alleging that their proposed generic product does not infringe on existing patents or that those patents are invalid. These certifications trigger a 30-month stay of FDA approval of the generic drug while patent litigation is resolved, unless the litigation concludes sooner.
The success of any challenge to US Patent 9,499,545 will depend on the strength of the prior art, the specific claim construction in court, and the overall legal strategy employed by the challenging party. The focus will likely be on the method of use claims, particularly regarding the definition of "effective amount" and the specific patient population for treating PBC.
What are the Implications for R&D and Investment Decisions?
The analysis of US Patent 9,499,545 and the broader patent landscape for obeticholic acid has significant implications for R&D strategies and investment decisions in the pharmaceutical sector, particularly in liver disease therapeutic areas.
For R&D:
-
Pipeline Differentiation: Companies developing competing therapies for PBC or NASH must carefully navigate the existing patent thicket. This necessitates identifying therapeutic targets or mechanisms of action that are distinct from OCA and not covered by existing patents. Innovation in novel compounds, different therapeutic pathways, or improved delivery systems will be critical.
-
Freedom to Operate (FTO): Thorough FTO analyses are essential before investing heavily in the development of new drugs. This involves identifying all relevant patents, assessing their scope and enforceability, and determining whether a new product or process would infringe on existing IP.
-
New Indication Exploration: While US Patent 9,499,545 specifically covers PBC, Intercept and other entities are researching OCA for other liver conditions, such as NASH. Any R&D efforts in new indications must consider the patent landscape for those specific uses. New patents covering novel uses are a crucial strategy for extending exclusivity.
-
Process and Formulation Innovation: Opportunities exist in developing novel, more cost-effective manufacturing processes for OCA or improved formulations that offer patient benefits (e.g., reduced dosing frequency, fewer side effects). These can form the basis for new patent filings.
For Investment Decisions:
-
Market Exclusivity Assessment: Investors must precisely understand the duration and strength of market exclusivity for Ocaliva. This involves analyzing the expiration dates of all key patents, including PTEs, and assessing the likelihood of successful patent challenges. The longer the effective exclusivity period, the more predictable the revenue stream for Intercept, but the longer the wait for generic entry.
-
Competitive Landscape Analysis: Identifying companies with pipeline candidates that could disrupt the market post-exclusivity is vital. Analyzing the R&D pipelines of competitors and their patent strategies provides insights into future market dynamics.
-
Valuation of Intercept Pharmaceuticals: The value of Intercept is directly tied to Ocaliva's market performance, which is underpinned by its patent protection. Investors will scrutinize the strength and longevity of this protection when assessing the company's valuation and future growth potential.
-
Risk Mitigation: Understanding patent litigation risks is paramount. High-cost, prolonged litigation can impact a company's financial health and delay or prevent market entry for generic competitors. Investors should assess the company's historical litigation success rates and its patent defense strategies.
-
Investment in Generic Competitors: For investors interested in the generic pharmaceutical space, the expiration dates of key patents for Ocaliva represent significant opportunities for market entry, provided they can successfully navigate FTO and regulatory hurdles.
The strategic layering of patents, from composition of matter to method of use and formulation, is a common and effective strategy in the pharmaceutical industry to maximize market exclusivity. US Patent 9,499,545 is a prime example of a method of use patent that extends the commercial life of a drug beyond the expiration of its initial composition of matter patents.
Key Takeaways
- US Patent 9,499,545 specifically claims the method of treating primary biliary cholangitis (PBC) using obeticholic acid (OCA).
- The patent defines effective dosage ranges and targets patient populations with an inadequate response to UDCA, reinforcing its therapeutic specificity.
- The broader patent landscape for OCA includes foundational composition of matter patents (now expired), as well as patents covering formulations and method of use.
- Patent Term Extension (PTE) and Orphan Drug Exclusivity (ODE) significantly extend Ocaliva's market exclusivity beyond the statutory expiration of individual patents.
- Patent challenges, including invalidity and non-infringement claims, are common risks, potentially involving administrative reviews (PGR, IPR) and district court litigation.
- For R&D, understanding the existing patent landscape is critical for identifying opportunities for differentiated therapies and conducting Freedom to Operate analyses.
- For investors, a precise assessment of patent expiration dates, PTEs, regulatory exclusivities, and litigation risks is essential for evaluating market exclusivity and company valuations.
Frequently Asked Questions
1. When does United States Patent 9,499,545 officially expire?
The statutory expiration date of United States Patent 9,499,545, without considering any extensions, is November 22, 2033. However, this date is subject to extension through Patent Term Extension (PTE) due to the FDA regulatory review period.
2. Does United States Patent 9,499,545 cover the obeticholic acid molecule itself?
No, US Patent 9,499,545 primarily covers the method of using obeticholic acid to treat primary biliary cholangitis. The composition of matter for obeticholic acid was covered by earlier, now expired, patents.
3. What are the primary risks associated with patent enforcement for US Patent 9,499,545?
Key risks include legal challenges to the patent's validity (e.g., based on prior art, obviousness) and claims of non-infringement by potential competitors. These can lead to costly and time-consuming litigation.
4. How does Patent Term Extension (PTE) affect the exclusivity period of Ocaliva?
PTE compensates for the time lost during the FDA approval process, thereby extending the effective expiration date of the patent. This directly prolongs the period of market exclusivity for Ocaliva against generic competition.
5. Are there any known patent litigations specifically challenging US Patent 9,499,545?
While specific ongoing litigation details can change rapidly, it is typical for method of use patents for commercially successful drugs like Ocaliva to be targets of patent challenges by generic manufacturers. Companies intending to market generic versions of Ocaliva will likely scrutinize US Patent 9,499,545 and related patents as part of their Hatch-Waxman Act strategy.
Citations
[1] United States Patent 9,499,545. (2016). Use of Obeticholic Acid for Treatment of Primary Biliary Cholangitis. Intercept Pharmaceuticals, Inc. Retrieved from USPTO Patent Full-Text and Image Database.
[2] United States Patent 6,353,045. (2002). FXR agonists. Dartmouth College. Retrieved from USPTO Patent Full-Text and Image Database.
[3] United States Patent 8,541,418. (2013). Obeticholic Acid Formulations and Methods of Use. Intercept Pharmaceuticals, Inc. Retrieved from USPTO Patent Full-Text and Image Database.
[4] U.S. Food and Drug Administration. (n.d.). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Retrieved from FDA website.
[5] Hatch-Waxman Act (Drug Price Competition and Patent Term Restoration Act of 1984). Public Law 98-417.
